Skip to main content
PMC home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;27(3):197–206. [Article in Spanish] doi: 10.1016/S0212-6567(01)78797-5

Proyecto COMBO

A Goday Arno, J Franch Nadal, A Goday Arno, M Mata Cases, F Álvarez Guisasola, J Díez Espino, I Fernández Fernández, D Tórtola Graner, D Acosta Delgado, M Aguilar Diosdado, JL Herrera Pombo, L Felipe Pallardo
PMCID: PMC7677957  PMID: 11262327

The content is available as a PDF (128.9 KB).

Criterios y pautas de terapia combinada en la diabetes tipo 2.Documento de consenso (I)

Bibliografía General

  • 1.Klein R. Hyperglicemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258–268. doi: 10.2337/diacare.18.2.258. [DOI] [PubMed] [Google Scholar]
  • 2.The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401. [DOI] [PubMed] [Google Scholar]
  • 3.Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6 years study. Diabetes Res Clin Frac. 1995;28:103–117. doi: 10.1016/0168-8227(95)01064-k. [DOI] [PubMed] [Google Scholar]
  • 4.United Kingdom Prospective Diabetes Study Group Intensive blood-glucose control with sulfonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–852. [PubMed] [Google Scholar]
  • 5.United Kingdom Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–864. [PubMed] [Google Scholar]
  • 6.Vijan S., Hofer T.P., Hayward R.A. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:195–788. doi: 10.7326/0003-4819-127-9-199711010-00003. [DOI] [PubMed] [Google Scholar]
  • 7.UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) BMJ. 1998;317:703–713. [PMC free article] [PubMed] [Google Scholar]
  • 8.American Diabetes Association Standards of medical care for patients with diabetes mellitus. Clinical practice recommendations. Diabetes Care. 2000;23(Supl 1):32–42. [Google Scholar]
  • 9.Canadian Diabetes Association 1998 clinical guidelines for the management of diabetes in Canada. CMAJ. 1998;159(Supl 8):1–29. [PMC free article] [PubMed] [Google Scholar]
  • 10.European Diabetes Policy Group 1998-1999 A desktop guide to type 2 diabetes mellitus. Diabetic Med. 1999;16:716–730. [PubMed] [Google Scholar]
  • 11.Grupo de Estudio de la Dabetes en Atención Primaria de Salud (GEDAPS) Harcourt Brace; Madrid:: 2000. Guía para el tratamiento de la diabetes tipo 2 en la atención primaria (3.a ed.) [Google Scholar]
  • 12.Lebovitz H.E. American Diabetes Association; Alexandria:: 1998. Therapy for diabetes mellitus and related disorders (3.a ed.) [Google Scholar]
  • 13.De Fronzo R.A. Pharmacologic therapy for type 2 Diabetes Mellitus. Ann Intern Med. 1999;131:281–303. doi: 10.7326/0003-4819-131-4-199908170-00008. [DOI] [PubMed] [Google Scholar]
  • 14.Haffner S., Lehto S., Ronnemaa T., Pyorala K., Laakson M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404. [DOI] [PubMed] [Google Scholar]

Bibliografía Monoterapia

  • 15.Lebovitz H.E. Insulin secretagogues: old and new. Diabetes Rev. 1999;7:139–153. [Google Scholar]
  • 16.Turner R., Cull C., Holman R. UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136–145. doi: 10.7326/0003-4819-124-1_part_2-199601011-00011. [DOI] [PubMed] [Google Scholar]
  • 17.Rosenstock J., Samols E., Muchmore D.B., Schneider J. The Glymepiride Study Group. Glymepiride, a new once-daily suifonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care. 1996;19:1194–1200. doi: 10.2337/diacare.19.11.1194. [DOI] [PubMed] [Google Scholar]
  • 18.Draeger K.E., Wernicke-Panten K., Lomp H.J., Schuler E., Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glymepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res. 1996;28:419–425. doi: 10.1055/s-2007-979830. [DOI] [PubMed] [Google Scholar]
  • 19.Goldberg R.B., Holvey S.M. Schnelder. A dose-response study of glymepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:849–856. doi: 10.2337/diacare.19.8.849. [DOI] [PubMed] [Google Scholar]
  • 20.Sonnenberg G.E., Garg D.C., Weidler D.J., Dixon R.M., Jaber L.A., Bowen A.J. Short-term comparison of onceversus twice-daily administration of glymepiride in patients with non insulin-dependent diabetes mellitus. Ann Pharmacother. 1997;31:671–676. doi: 10.1177/106002809703100601. [DOI] [PubMed] [Google Scholar]
  • 21.Cusi K., De fronzo R.A. Metformin: a review of its metabolic effects. Diabetes Rev. 1998;6:89–131. [Google Scholar]
  • 22.Johansen K. Efficacy of metformin in the treatment of NIDDM. Metaanalysis. Diabetes Care. 1999;22:33–37. doi: 10.2337/diacare.22.1.33. [DOI] [PubMed] [Google Scholar]
  • 23.Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohif J.L. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, doseresponse trial. Am J Med. 1997;102:491–497. doi: 10.1016/s0002-9343(97)00254-4. [DOI] [PubMed] [Google Scholar]
  • 24.Defronzo R., Goodman A. Efficacy of metformin in patients with NIDDM. N Engl J Med. 1995;333:541–549. doi: 10.1056/NEJM199508313330902. [DOI] [PubMed] [Google Scholar]
  • 25.Stacpoole P.W. Metformin and lactic acidosis Guilt by association? Diabetes Care. 1998;21:1587–1588. doi: 10.2337/diacare.21.10.1587. [DOI] [PubMed] [Google Scholar]
  • 26.Bayraktar M., Adalar N., Van Thiel D.H. A comparison of acarbose versus metformin as an adjunt therapy in sulfonylurea-treated NIDDM patients. Diabetes Care. 1996;19:252–259. doi: 10.2337/diacare.19.3.252. [DOI] [PubMed] [Google Scholar]
  • 27.Scheen A.J. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metabolism. 1998;24:311–320. [PubMed] [Google Scholar]
  • 28.Coniff R., Shapiro J.A., Robbins D., Kleinfield R., Seaton T., Beisswenger P. Reduction of glycosilated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dosecomparison study. Diabetes Care. 1995;18:817–824. doi: 10.2337/diacare.18.6.817. [DOI] [PubMed] [Google Scholar]
  • 29.Hoffman J., Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care. 1994;17:561–566. doi: 10.2337/diacare.17.6.561. [DOI] [PubMed] [Google Scholar]
  • 30.Holman R.R., Turner R.C., Cull C.A. on behalf of the UKPDS Study Group. A randomized double-blind trial of Acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care. 1999;22:960–964. doi: 10.2337/diacare.22.6.960. [DOI] [PubMed] [Google Scholar]
  • 31.Segal P., Felg P.U., Scherntbaner G., Ratzmann K.P., Rybka J., Petzinna D. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 1997;20:687–691. doi: 10.2337/diacare.20.5.687. [DOI] [PubMed] [Google Scholar]
  • 32.Owens D.R. Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med. 1998;15(Supl 4):28–36. doi: 10.1002/(sici)1096-9136(1998120)15:4+<s28::aid-dia748>3.3.co;2-k. [DOI] [PubMed] [Google Scholar]
  • 33.Marbury T., Huang W.C., Strange P., Lebovitz H. Repaglinide versus glyburide a one-year comparison trial. Diabetes Res Clin Pract. 1999;43:155–166. doi: 10.1016/s0168-8227(99)00002-9. [DOI] [PubMed] [Google Scholar]
  • 34.Iwamoto Y., Kosaka k., Kuzuya T., Akaa Y. Effects of Troglitazone. A new hipoglycernic agent in patients with NIDDM poorly controlled by diet. Diabetes Care. 1996;19:151–155. doi: 10.2337/diacare.19.2.151. [DOI] [PubMed] [Google Scholar]
  • 35.Plosker G.L., Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 1999;57(3):409–438. doi: 10.2165/00003495-199957030-00014. [DOI] [PubMed] [Google Scholar]
  • 36.Watkins P., Whitcomb R. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338:916–917. doi: 10.1056/NEJM199803263381314. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES